Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus NETROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAGEN versus NETROMYCIN.
BRISTAGEN vs NETROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Netromycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in bacteria.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
4-6 mg/kg IV once daily for serious infections; 1.5-2 mg/kg IV every 8 hours for gram-negative infections. Administered as intravenous infusion over 30-60 minutes.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
Terminal elimination half-life is 2-3 hours in adults with normal renal function, but may extend to 24-48 hours in patients with impaired renal function.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic